Chronically administered immunotherapy with low-dose IL-2 and IFN-α in metastatic renal cell carcinoma: A feasible option for patients with a good prognostic profile

Oncology

Volumn 76, Issue 1, 2008, Pages 69-76

  Vaglio, Augusto ^a   Alberici, Federico ^a   Maggiore, Umberto ^a   Buti, Sebastiano ^b   Potenzoni, Domenico ^c   Passalacqua, Rodolfo ^b   Buzio, Carlo ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b CREMONA HOSPITAL   (Italy)

^c Fidenza Hospital   (Italy)

Author keywords

Immunotherapy; Interferon ; Interleukin 2; Prognostic factor; Renal cell carcinoma

Indexed keywords

FLUOROURACIL; GEMCITABINE; PARACETAMOL; PROTON PUMP INHIBITOR; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HEART ARRHYTHMIA; HEARTBURN; HIGH RISK POPULATION; HUMAN; IMMUNOTHERAPY; KIDNEY CARCINOMA; KIDNEY METASTASIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT REDUCTION; WORLD HEALTH ORGANIZATION;

CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 56849112215     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000178810     Document Type: Article

References (30)

1. Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC, Conaway JW: Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA 2000;97:10430-10435.
2. Pantuck AJ, Zeng G, Belldegrun AS, Figlin RA: Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res 2003;9:4641-4652.
3. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-134.
4. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-124.
5. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-2281.
6. Pouessel D, Culine S: High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur Urol 2008;53:376-381.
7. Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA: High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer: responses, treatment-related morbidity, and histologic findings. JAMA 1986;256:3117-3124.
8. Lopez Hanninen E, Kirchner H, Atzpodien J: Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol 1996;155:19-25.
9. Sleijfer DT, Janssen RA, Buter J, de Vries EG, Willemse PH, Mulder NH: Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol 1992;10:1119-1123.
10. McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, Tretter CP, Urba WJ, Smith JW, Margolin KA, Mier JW, Gollob JA, Dutcher JP, Atkins MB: Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23:133-141.
11. Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, Seipp CA, Rogers-Freezer L, Morton KE, White DE, Liewehr DJ, Merino MJ, Rosenberg SA: Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;21:3127-3132.
12. Buzio C, Andrulli S, Santi R, Pavone L, Passalacqua R, Potenzoni D, Ferrozzi F, Giacosa R, Vaglio A: Long-term immunotherapy with low-dose interleukin-2 and interferon-alpha in the treatment of patients with advanced renal cell carcinoma. Cancer 2001;92:2286-2296.
13. Raspadori D, Lauria F, Ventura MA, Tazzari PL, Ferrini S, Miggiano MC, Rondelli D, Tura S: Low doses of rIL2 after autologous bone marrow transplantation induce a 'prolonged' immunostimulation of NK compartment in high-grade non-Hodgkin's lymphomas. Ann Hematol 1995;71:175-179.
14. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.
15. Sobin L, Wittekind C: TNM Classification of Malignant Tumors, ed 6. New York, Wiley-Liss, 2002, pp 198-200.
16. Fuhrman SA, Lasky LC, Limas C: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6:655-663.
17. Buzio C, De Palma G, Passalacqua R, Potenzoni D, Ferrozzi F, Cattabiani MA, Manenti L, Borghetti A: Effectiveness of very low doses of immunotherapy in advanced renal cell cancer. Br J Cancer 1997;76:541-544.
18. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
19. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981;47:207-214.
20. Negrier S, Escudier B, Gomez F, Douillard JY, Ravaud A, Chevreau C, Buclon M, Perol D, Lasset C: Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. Ann Oncol 2002;13:1460-1468.
21. Giacosa R, Santi R, Vaglio A, Pavone L, Ferrozzi F, Passalacqua R, Buzio C: 'Late' regressions of metastases from renal cancer after a period of disease progression continuing the same intermittent low dose immunotherapy regimen. Acta Biomed 2004;75:126-130.
22. Pavone L, Andrulli S, Santi R, Majori M, Buzio C: Long-term treatment with low doses of interleukin-2 and interferon-alpha: immunological effects in advanced renal cell cancer. Cancer Immunol Immunother 2001;50:82-86.
23. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17:2530-2540.
24. Vaglio A, Buzio L, Cravedi P, Pavone L, Garini G, Buzio C: Prognostic significance of albuminuria in patients with renal cell cancer. J Urol 2003;170:1135-1137.
25. Atzpodien J, Kirchner H, Jonas U, Bergmann L, Schott H, Heynemann H, Fornara P, Loening SA, Roigas J, Muller SC, Bodenstein H, Pomer S, Metzner B, Rebmann U, Oberneder R, Siebels M, Wandert T, Puchberger T, Reitz M: Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 2004;22:1188-1194.
26. Atzpodien J, Royston P, Wandert T, Reitz M: Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 2003;88:348-353.
27. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289-296.
28. Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, Mazumdar M: Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22:454-463.
29. Cohen HT, McGovern FJ: Renal-cell carcinoma. N Engl J Med 2005;353:2477-2490.
30. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103-2111.